Identification | Back Directory | [Name]
2H-Pyran-4-carbonitrile, 4-[[[4-[5-chloro-2-[[trans-4-[[(1R)-2-methoxy-1-methylethyl]amino]cyclohexyl]amino]-4-pyridinyl]-2-thiazolyl]amino]methyl]tetrahydro- | [CAS]
2247481-08-7 | [Synonyms]
2H-Pyran-4-carbonitrile, 4-[[[4-[5-chloro-2-[[trans-4-[[(1R)-2-methoxy-1-methylethyl]amino]cyclohexyl]amino]-4-pyridinyl]-2-thiazolyl]amino]methyl]tetrahydro- | [Molecular Formula]
C25H35ClN6O2S | [MOL File]
2247481-08-7.mol | [Molecular Weight]
519.1 |
Chemical Properties | Back Directory | [Boiling point ]
694.7±65.0 °C(Predicted) | [density ]
1.28±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
9.13±0.40(Predicted) | [color ]
White to yellow |
Hazard Information | Back Directory | [Uses]
Tambiciclib is a novel, highly selective CDK9 inhibitor critical for regulating transcription elongation. Tambiciclib demonstrated significant in vitro and in vivo efficacy against acute myeloid leukemia (AML)[1]. | [IC 50]
CDK9 | [References]
[1] Wang L, et al. Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models. Invest New Drugs. 2020 Oct;38(5):1272-1281. DOI:10.1007/s10637-019-00868-3 |
|
|